Event Details

Verastem Inc at 2013 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer

Oct 27, 2013 at 12:00 PM EDT to Oct 30, 2013 at 11:59 PM EDT
Title
Verastem Inc at 2013 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer
Date / Time
Oct 27, 2013 at 12:00 PM EDT to Oct 30, 2013 at 11:59 PM EDT

Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 as Maintenance Therapy in Subjects with Malignant Pleural Mesothelioma which has Not Progressed on at least 4 Cycles of Pemetrexed/Platinum Therapy (COMMAND)

Abstract #: P2.14-014

Date and Time: Tuesday, October 29, 2013 9:30 – 4:30 PM

Session: Poster Session 2; Mesothelioma

Location: Exhibit Hall, Ground Level

Title: Malignant Mesothelioma Lacking Merlin Shows Enhanced Sensitivity to the FAK Inhibitor VS-6063: Evaluation of Merlin/NF2 Status in Clinical Samples

Abstract #: P2.06-048

Date and Time: Tuesday, October 29, 2013 9:30 – 4:30 PM

Session: Poster Session 2; Prognostic and Predictive Biomarkers

Location: Exhibit Hall, Ground Level

Investor Contact

getty
John Doyle

VP Investor Relations & Finance
781.292.4279
jdoyle@verastem.com

Joe Rayne

Argot Partners
617.340.6075
joseph@argotpartners.com